Concierge gives you timely BUY and SELL alerts on ASX-listed stocks
Upgrade your Membership
Save $$$
ASX Life Sciences stocks: Mr. Biotech thinks that 2023 could be a very good year to buy them
Marc Kennis, May 1, 2023
ASX Life Sciences stocks are back, baby!
ASX Life Science stocks have suffered heavily in 2022 due to investors shifting out of risk assets, resulting in a bear market for biotech and medical devices. However, our own Mr. Biotech, Stuart Roberts, believes that now is a good time to buy ASX Life Science stocks, as many high-quality businesses are being overlooked due to poor sentiment.
The bear market has wiped out stocks that were overvalued due to COVID-19 enthusiasm and attracted tourist investors. Stuart sees this as an opportunity to invest in undervalued companies with potential for disruption, although they are currently trading below net asset backing and below cash.
He says stocks to look at include Race Oncology (ASX: RAC), Paradigm Biopharmaceuticals (ASX: PAR), Prescient Therapeutics (ASX: PTX).
Stuart Roberts on AusBiz talking ASX Life Sciences stocks
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
There’s no credit card needed – the trial expires automatically.
Stocks Down Under
Average rating: 0 reviews
Blog Categories
Recent Posts
So your company announced a non-binding MOU: Is it a genuine deal or desperate puffery?
When you’re invested in a microcap stock, you might hear it has signed a ‘non-binding MOU’ (short for Memorandum of…
How are stock market indices like the ASX 200 determined?
Stock market indices like the ASX 200 and S&P 500 are used as barometers for the performance and overall health…
Currency hedging: Here’s how it works and why it’s so important to so many companies and investors
You’ll commonly hear the term ‘currency hedging’. It is undertaken by many companies as part of the ordinary course of…